Rate of serious adverse events · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review
Intervention not reported
Non‐serious systemic adverse events (all included studies) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious systemic adverse events (all included studies)… (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious local adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (6 months · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
Serious adverse events (6 months · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Serious adverse events (3 to 4 weeks · children with stable wrist fracture, predominantly buckle (torus) fracturesa
1 finding from 1 review
All serious adverse events · children
Rotarix leads to lower all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.85 [0.76, 0.95]
9 studies · 77069 participants
High
RR 0.9 [0.77, 1.05]
10 studies · 7674 participants
High
RR 0.89 [0.72, 1.1]
12 studies · 18971 participants
High
All serious adverse events · children
RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found